SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing intense community debate and high volatility expectations, as traders grapple with bearish technical signals and predictions of a broader market correction, while others anticipate a potential rebound amidst ongoing discussions of economic health and the widespread impact of AI.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as Hapag-Lloyd's $35 per share acquisition offer drives fervent community discussion, focusing on the potential for a short squeeze, critical Israeli government approval, and the outlook for dividends prior to the deal's anticipated late 2026 completion.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is trending as its merger with quantum technology leader Infleqtion concludes with exceptionally low redemptions, preserving substantial capital and fueling intense community anticipation for its upcoming NYSE debut as INFQ, which many believe is significantly undervalued compared to peers given its strong government and space contracts.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is trending as market participants anticipate a potential volatility spike, fueled by ongoing geopolitical tensions, upcoming economic releases, and Q3 earnings reports, leading many to position for a significant market pullback while others caution against holding volatility products long-term due to decay.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings is trending as activist investor Elliott Management reportedly built a significant stake, aiming to drive changes and help the company catch up with rivals. This news is generating excitement among investors hopeful for operational improvements and a rebound, though some remain cautious amid ongoing debate around the recent CEO transition and perceived market manipulation.

Parsons Corp. is a disruptive technology provider in the national security and global infrastructure markets, with capabilities across cyber and intelligence, space and missile defense, transportation, environmental remediation, urban development, and critical infrastructure protection. It operates through the Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is involved in advanced technologies, including cybersecurity, missile defense systems, C5ISR, space launch and situational awareness, geospatial intelligence, RF signals intelligence, nuclear and chemical waste remediation, and engineering services. The Critical Infrastructure segment offers integrated design and engineering services for complex physical and digital infrastructure around the globe. The company was founded by Ralph Monroe Parsons on June 12, 1944 and is headquartered in Chantilly, VA.

Parsons Corp

Parsons is trending after losing a major FAA contract and facing renewed uncertainty around a confidential federal program, amplified by broader market concerns over government spending efficiency. However, many in the community view the sharp pullback as an oversold buying opportunity, highlighting the company's extensive backlog and robust position in critical infrastructure, cyber, and defense sectors.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to its strategic acquisition of Diligent Robotics, expanding its autonomous platform into the healthcare sector, which is bolstered by recent bullish analyst coverage and Nvidia CEO Jensen Huang's public endorsement. This is driving community discussion around its 'Physical AI' growth potential amidst ongoing questions about valuation and profitability.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience is generating significant conversation following its NASDAQ listing and recent capital raise, with community members divided over the prospects of its lead Duchenne Muscular Dystrophy (DMD) drug, SAT-3247. While some investors see its novel muscle regeneration mechanism and anticipated Phase 2 data as a potential breakthrough, others express skepticism concerning financial actions and the inherent challenges of developing early-stage biopharma treatments.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending due to immense anticipation for topline Phase 3 superiority data for its wet AMD treatment, Axpaxli, expected Tuesday, as community excitement builds around potential market redefinition, strong institutional confidence, and persistent acquisition rumors.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is a focal point of intense community discussion, driven by heightened anticipation for federal cannabis rescheduling to Schedule III and its expanded UK pharmaceutical access, with bulls expecting a massive short squeeze and significant upside despite lingering skepticism over valuation and management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...

Wall Street Zen Upgrades MiNK Therapeutics (NASDAQ:INKT) to "Hold"

Wall Street Zen raised shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday...

MiNK Therapeutics (NASDAQ:INKT) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut shares of MiNK Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised MiNK Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has earned an average rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat reports. One equities...

Wall Street Zen Downgrades MiNK Therapeutics (NASDAQ:INKT) to Sell

Wall Street Zen downgraded MiNK Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Wall Street Zen upgraded shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat reports. One...

MiNK Therapeutics (NASDAQ:INKT) Posts Earnings Results, Beats Expectations By $0.21 EPS

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

MiNK Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$11.04
Prev Close	$11.04
Open	$11.00
Dividend Yield	0.00%
50-Day Moving Average	$11.87
Beta	0.58
Avg. Volume	10,867.45
PE Ratio	-3.64

52-Week High	$76.00
52-Week Low	$6.34
Market Capitalization	$51.82M
EPS (Annual)	-$2.86
Price to Book	-3.76
Revenue Per Employee	$0.00

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INKT News

INKTMiNK Therapeutics Inc